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KAJIAN MEKANISME SITOTOKSIK DAN PERANAN mikroRNA DALAM 
SEL MDA-MB-231 YANG DIOLAH DENGAN FRAKSI ETIL ASETAT 




Phaleria macrocarpa merupakan tumbuhan ubatan yang terkenal yang 
mempamerkan sitotoksiti terhadap pelbagai jenis sel kanser. Objektif kajian ini 
adalah untuk mengenalpasti kesan sitotoksik secara in vitro dengan mengunakan 
ujian biokimia melalui pengawalaturan miRNA dalam MDA-MB-231 yang diolah 
dengan PMEAF. Jumlah fenolik dalam PMEAF adalah sebanyak 14.91 ± 0.97 mg 
GAE/g. Keputusan ujian sitotoksisiti MTT dan CyQuant menunjukkan bahawa 
PMEAF adalah agen anti-kanser yang berpotensi dengan  nilai purata IC50 sebanyak 
18.10 μg/mL. Ciri-ciri kematian sel apoptotik termasuk pengecutan sel, blebs 
membran, kondensasi kromatin dan pembentukan badan apoptotik dapat diperhatikan 
melalui pelbagai teknik mikroskopi seperti mikroskop cahaya, mikroskop hologram, 
mikroskop elektron transmisi (TEM) dan imbasan (SEM). Pewarnaan AO/PI dan 
analisis aliran sitometri dijalankan terhadap sel-sel MDA-MB-231 yang dirawat 
dengan PMEAF menunjukkan bahawa kematian sel secara perencatan apoptosis. 
Analisis aliran sitometri tentang kitaran sel menunjukkan bahawa pengumpulan sel-
sel MDA-MB-231 yang dirawat dengan PMEAF dalam fasa G0/G1 dan G2/M. 
Tambahan pula, aktiviti sitotoksisiti PMEAF juga meningkatkan penghasilan ROS 
dalam sel MDA-MB-231 dan secara konsisten merangsang kehilangan potensi 
membran mitokondria (∆ѱm). Keputusan kajian tentang profil protein membuktikan 
bahawa PMEAF meningkatkan penghasilan 9 jenis protein bersifat pro-apoptotik 
xxiii 
 
(Bax, Bid, caspase 3, caspase 8, cytochrome c, p21, p27, p53 dan SMAC) dan 
megurangkan penghasilan 4 jenis protein bersifat anti-apoptotik (Bcl-2, Bcl-w, XIAP 
dan survivin) dalam sel MDA-MB-231. PMEAF menyebabkan apoptosis dalam sel 
MDA-MB-231 melalui laluan intrinsik dengan penyertaan oleh caspases, perencatan 
kitaran sel pada fasa G0/G1 dan G2/M dengan mekanisma diperantara oleh p53.  
Kajian mengenai pengawalaturan miRNA dalam sel MDA-MB-231 yang 
dirawat dengan PMEAF telah mengenalpasti 10 miRNAs dengan peningkatan 
pengawal aturan  dan 10 miRNA dengan penurunan pengawal aturan dalam sel-sel 
MDA-MB-231 dengan menggunakan perkhidmatan IIlumina, platform Hi-Seq2000 
daripada Next Generation Sequencing (NGS). Sebanyak 606 gen sasaran oleh 10 
miRNA peningkatan pengawalaturan dan 517 gen sasaran oleh 10 miRNA dengan 
penurunan pengawalaturan telah diramalkan berdasarkan kaedah analisis 
berkomputer dan telah disahkan dalam pangkalan data “miRGate”. Sementara itu, 
keputusan daripada Sumber Bioinformatik v6.8 DAVID telah menentukan fungsi 
anotasi penglibatan miRNA dengan peningkatan pengawalaturan berperanan untuk 
mengurangkan experasi onkogen dalam laluan kanser dan miRNA dengan penurunan 
pengawal aturan berperanan dalam meningkatkan eksperasi gen perencatan tumor 
dalam laluan apoptotic. Kesimpulannya, kajian ini membuktikan bahawa PMEAF 
adalah agen anti-kanser yang menunjukkan tahap sitotoksisiti yang tinggi terhadap 
sel MDA-MB-231 dan merangsang kematian sel bersifat apoptotik melalui 
pengawalaturan miRNA. PMEAF mungkin menjadi calon yang baik untuk 




STUDY OF CYTOTOXIC MECHANISM AND THE ROLE OF microRNA IN 
MDA-MB-231 CELL LINES TREATED WITH Phaleria macrocarpa (Boerl.) 
FRUIT ETHYL ACETATE FRACTION (PMEAF) 
 
ABSTRACT 
Phaleria macrocarpa is a well-known medicinal plant which exhibited 
cytotoxicity against various cancerous cells. The objective of this study was to 
determine the in vitro cytotoxicity effect by biochemical assay through the regulation 
of miRNAs on MDA-MB-231 treated with Phaleria macrocarpa ethyl acetate 
fraction (PMEAF). Total phenolic content of PMEAF was expressed as 14.91 ± 0.97 
mg GAE/g. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) and CyQuant Cell Proliferation assay results indicated that PMEAF is a 
potential anticancer agent with the average IC50 values of 18.10 µg/mL. The 
characteristic of apoptotic cell death includes cell shrinkage, membrane blebs, 
chromatin condensation as well as the formation of apoptotic bodies and these were 
observed through light microscopy, holographic microscopy, transmission electron 
microscopy (TEM) and scanning electron microscope (SEM). The AO/PI staining 
and flow cytometric analysis of MDA-MB-231 cells treated with PMEAF showed 
apoptotic cell death. The cell cycle analysis by flow cytometry analysis revealed that 
the accumulation of PMEAF treated MDA-MB-231 cells in G0/G1 and G2/M-phase 
of the cell cycle. Moreover, the PMEAF exert cytotoxicity by increasing the ROS 
production in MDA-MB-231 cells which consistently stimulated the loss of 
mitochondrial membrane potential (∆Ψm). The PMEAF stimulated the expression of 
nine pro-apoptotic proteins (Bax, Bid, caspase 3, caspase 8, cytochrome c, p21, p27, 
p53 and SMAC) and suppressed the four anti-apoptotic proteins (Bcl-2, Bcl-w, XIAP 
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and survivin) in MDA-MB-231 cells. PMEAF induced apoptosis in MDA-MB-231 
cells through intrinsic pathway with the participation of caspases, G0/G1 and G2/M-
phases cell cycle arrest by p53-mediated mechanism. The PMEAF treatment against 
MDA-MB-231 cells identified 10 upregulated and 10 downregulated miRNAs by 
using IIlumina, Hi-Seq2000 platform of Next Generation Sequencing (NGS). A set 
of 606 target genes of 10 upregulated miRNAs and 517 target genes of 10 
downregulated miRNAs were predicted based on computational and validated 
databases by using miRGate DB Query. Meanwhile, results from DAVID 
Bioinformatics Resources 6.8 specified the functional annotation of the upregulated 
miRNAs involvement in cancer pathway by suppressing the oncogenes and down 
regulating miRNAs by expressing the tumour suppressor genes in regulation of 
apoptosis pathway. In conclusion, the results of this study proved that PMEAF is a 
promising anticancer agent with high cytotoxicity against MDA-MB-231 breast 
cancer cells and it induced apoptotic cell death mechanism through the regulation of 
miRNAs. PMEAF might be the best candidate for developing more potent anticancer 




CHAPTER 1.0: INTRODUCTION 
 
1.1 Overview and rationale of the study 
Breast cancer is commonly diagnosed as invasive cancer in women worldwide and the 
second leading cause of cancer death which affects about 400,000 patients every year 
(Gluz et al., 2009; Siegel et al., 2016). Breast cancer occurs due to the abnormal cells 
growth surrounding the breast tissues and proliferates into neighbouring cell or 
progression of secondary malignant tumour growths known as ‘metastasis”. In recent 
years, breast cancer incidences are increasing vastly due to difficulty in treating cancer 
patients since different stages of tumour exhibited different treatment responses. Most 
of the chemotherapeutic drugs, namely Tamoxifen, Doxorubicin, Docetaxel are only 
effective in one third of breast cancer patients (Fisher et al., 2005). Thus, searching for 
new alternative and complementary medicine which are less toxic as a cure for breast 
cancer is in great need. In a review focusing on the survival of breast cancer patients 
and their intake of fruits and vegetables, five of the eight cohort studies showed a direct 
relationship between vegetable and fruit intake and survival of breast cancer patient, 
with a 20 - 90% reduction in death risk (Rock and Demark-Wahnefried, 2002). 
Moreover, phytochemicals from fruits and vegetables are primary contributors in 
preventing the cancer cells progression and increasing the survival rate of breast cancer 
patients (Jung et al., 2013). This awakens the interest of researchers in isolating the 
bioactive compounds from fruits, vegetables and natural products as competent 
anticancer drugs. Although the outcome of crude medicinal plants is usually slower in 
onset compared to commercial drugs, patients may benefit through less side effects of 




In view of that fact, this study was conducted to pave a way in developing new 
anticancer agents from the traditional medicinal plant, Phaleria macrocarpa (Scheff.) 
Boerl (Thymelaceae) for the prevention of breast cancer development. P. macrocarpa 
is a popular medicinal plant rich with various phytochemicals and commonly  used in 
the traditionally medicine to treat various diseases including cancer, impotency, heart 
disease, kidney disorders, diabetic mellitus and skin diseases (Zhang et al., 2006). 
Native Indonesians have been practising the consumption of P. macrocarpa stem, 
fruit, seed or leaf in boiled water extract which revealed that the plant has no side 
effects and showed that it is harmless (Faried et al., 2007). This plant species produces 
an ample of secondary metabolites such as tannins, terpenoids, alkaloids and 
flavonoids which are favourable for drugs development or nutritional supplements 
(Hendra et al., 2011). Gallic acid isolated from the fruits of P. macrocarpa has proven 
to inhibit the proliferation of various cancerous cells including human esophageal 
cancer (TE-2), gastric cancer (MKN-28), colon cancer (HT-29), breast cancer (MCF-
7), cervical cancer (CaSki), and malignant brain tumor (CGNH-89 and CGNH-PM) 
(Faried et al., 2007). To date, there is no detailed study reporting on the mechanism of 
actions of P. macrocarpa fruit extracts particularly through the regulation of miRNAs. 
Therefore, this study was done to investigate the cytotoxic activities and cell death 
mechanism regulated by miRNA in relation to the cytotoxicity of P. macrocarpa 
against MDA-MB-231 breast cancer cells as a model. 
MicroRNA (miRNA) is a noncoding RNA with 18 to 25 nucleotides, which 
plays pivotal role as dysregulator of gene expression in biological activities including 
apoptosis, cellular differentiation and cancer cell proliferation (Garzon et al., 2010). 
The miRNA known as ‘oncogene’ when overexpressed in tumorigenesis while 
miRNAs also react as ‘tumour suppressor’ by downregulating the cancer-related gene 
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(Iorio and Croce, 2012). In order to identify the roles of miRNAs in tumorigenesis and 
development, it is worth scrutinizing the related miRNAs and putative target genes in 
the anticancer mechanism of P. macrocarpa ethyl acetate fraction (PMEAF) in MDA-
MB-231 breast cancer cell lines. Thus, high-throughput sequencing using next 
generation sequencing (NGS) technologies were used in this study to analyse data from 
Illumina (NGS Sequencing Data Library) based on mapping to miRBase v21 for 
detection of differentially expressed miRNAs in tumorigenesis (Wang et al., 2016). 
Subsequently, the target prediction database of miRGate Database Query was used 
through free online algorithms to identify putative target genes involved in mediating 
the cytotoxic effect of P. macrocarpa in MDA-MB-231 breast cancer cell lines. 
Besides, PhenomiR 2.0 database was used to analyse dysregulation of selected miRNA 
expression in diseases and other biological processes. Lastly, to finalize the selected 
upregulated and downregulated miRNAs, David Functional Annotation Tools v6.8 
was used for gene-annotation enrichment analysis, functional annotation clustering 
and KEGG pathway analysis. 
This study has been conducted by using MTT and CyQuant cytotoxicity assay, 
various microscopy methods, flow cytometry (Annexin V/PI) analysis, cell cycle 
analysis, Reactive Oxygen Species (ROS) determination and Mitochondrial 
Membrane Potential assay. Human Apoptosis Array Kit was used to analyse the 
expression profiles of apoptosis-related proteins such as Bcl-2, Bax, Bid, Bcl-w, 
Cytochrome c, p21, p27, p53, Caspase 3, Caspase 8, Survivin, XIAP and SMAC. The 
miRNA sequencing by Illumina Hi-Seq was done to explore the role of the putative 
miRNAs and their targeted genes as well as the involvement in the pathway of cell 






1.2 Research Objectives 
Therefore the current study was undertaken with the following objectives: 
 
1. To evaluate the cytotoxicity of P. macrocarpa ethyl acetate fraction (PMEAF) 
against MDA-MB-231 and Vero cells. 
2. To investigate the preliminary cytotoxicity mechanism of P. macrocarpa ethyl 
acetate fraction (PMEAF) on morphology and cytology of MDA-MB-231 cells 
by light, holographic, scanning and transmission electron microscope.  
3. To study the detailed cytotoxicity mechanism induced by P. macrocarpa ethyl 
acetate fraction (PMEAF) on MDA-MB-231 cells. 
4. To identify the putative miRNAs and target genes regulated by P. macrocarpa 
ethyl acetate fraction (PMEAF) on MDA-MB-231 cells through next 










CHAPTER 2.0: LITERATURE REVIEW 
 
2.1 Plants as potential natural product 
Natural product to be used in medicine is derived from various sources including   
native plants, microorganisms, marine organisms, terrestrial vertebrates and 
invertebrates (Chin et al., 2006). Medicinal plants have played an important role 
throughout the world in treating and preventing diseases   since ancient  times. The 
discovery of pure compounds as active principles in plants was first described at the 
beginning of the 19th century, and the art of exploiting natural products has become 
part of the molecular sciences. Plants do not only provide food and shelter but also 
help in curing human diseases and act as a splendid source of bioactive compounds 
with anticancer, antioxidant, antimicrobial and antiparasitic activity which has been of 
recent interest among researchers (Khan et al., 2010). The developments of natural 
products as medicine are due to their pharmacological activities and potential 
therapeutic uses. Indirectly, natural plant medicine represents a way to rescue valuable 
aspects of traditional culture. Drugs that are derived from natural products are effective 
in treating various diseases at specific characteristics with less or no side effects (Shah 
et al., 2013). This is due to the bioactive compounds in natural products which give 
benefits to the body by improving the immune system. Indirectly, naturally-derived 
drugs enable patients to withstand higher and more effective dosage of treatments such 
as chemotherapy without additional side effects (Bhadury et al., 2006). Besides that, 
patients from low income developing countries   claim  that natural products medicine 
are cheaper, effective and have less side effects if compared to synthetic drugs (Ahsan 
et al., 2009).  
6 
 
Research on medicinal plants has been supported worldwide. The major target 
of the research is the identification of the values of active compound in medicinal 
plants and the pharmacological investigation of the extracts which enhance their 
safety, effectiveness and constant activity. The World Health Organization (WHO) 
estimates that 80% of people in developing countries are on traditional medicine for 
their primary health care needs and about 85% of traditional medicine involves the use 
of plant extracts as sources of drugs. 
  
2.2 Phaleria macrocarpa  
2.2.1 General Description  
Phaleria macrocarpa (Scheff.) Boerl, a plant from Thymelaeceae family was first 
designated by Scheffer as Drimyspermum macrocarpum according to fruiting 
specimens collected by Teysmann near Dore, in western New Guinea (Angiosperm 
Phylogeny Group, 2003). P. macrocarpa, is commonly known as God's crown or 
Mahkota Dewa, is one of the Indonesian’s native medicinal plants that grow on the 
island of Papua. It is believed to have the ability to treat various diseases with an 
abundance of benefits. The plant has also been used traditionally by traditional healers 
in medical and health treatments (Azmir et al., 2014). The name “God's crown” given 
to this fruit implies that it descends from heaven, as godsend from divine powers to 
help mankind.   
 
2.2.2 Botanical Description  
It is a tree (Figure 2.1), including stem, leaves, flowers, fruits and thrives in loose, 
fertile soil at an altitude of 10  to 1200 m above sea level. The tree height ranges from 
1 to 18 m with sap exuding 1 m long root and its bark are brownish green and it has 
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white wood. The leaves are green in colour with the length from 7 to 10 cm and width 
ranging from 3 to 5 cm. The flowers are typically with 2 to 4 petals of green to maroon 
color. Seeds exist as 1 to 2 seeds per fruit and are brown, ovoid and anatropous. 
Although the herb is being used in both un-processed and processed form, however, 
the former can be poisonous and toxic (Yosie et al., 2011). P. macropcarpa fruit is of 
eclipse shape with a diameter of 3 cm. Fruits are green when unripen and become red 
on ripening (Hendra et al., 2011) where the flesh is white, fibrous and watery. It can 

































Figure 2.1: Phaleria macrocarpa. 
(1) A bunch of red ripe fruits, (2) Phaleria macrocarpa tree, (3) Green fruit 
and leaves. The pictures are taken from ECO HUB, Pusat Repositori Kearifan 











2.2.3 Taxonomical Classification 
 
 








Superdivision  Spermatophyta 






Species  Phaleria macrocarpa  
 
Source: Angiosperm Phylogeny Group, 2003. 
 
 
2.2.3(a) Common Names 
The Javanese referred to this tree as Makuto Dewo, Makuto rojo, Makuto queen, 
Makuta god, and ‘Pau’ (Susilawati et al., 2011). It is also called ‘Simalakama’ in 
Sumatra, Depok (West Java), ‘Mahkota Dewa’ in Malay, Crown of God or God’s 






The Latin name of plant is Phaleria macrocarpa (Scheff.) Boerl and synonyms are 
Phaleria papuana Warb var. Wichanii (Val) Back (Hou, 1960). Phaleria 
calantha Gilg, Phaleria papuana Warb. ex K. Schum. Lauterb., and Phaleria 
wichmannii Valeton.  
 
2.2.4 Distribution  
P. macrocarpa is an indigenous plant from Papua Island (Irian Jaya) or Papua New 
Guinea, more specifically in the area of Maprik about 110 km journey from the town 
of Wewak. A God's Crown tree was found at about nine meters in height bearing fruit 
on every branch. Centuries ago samples of the Mahkota Dewa tree were transported 
from the island of Papua by traditional Javanese medicine men and planted in the 
palace grounds of Solo and Jogyakarta. Its native habitat is terrestrial primary 
rainforest; it grows well in tropical areas especially in Malaysia and is known as a 
popular herbal plantation in the South Asian countries.  
 
2.2.5 Ethnomedicinal Uses 
Each part of this plant including fruits, seeds, stems and leaves have their own healing 
power. The fruits of P. macrocarpa have the ability to treat flu, rheumatism, heart 
diseases and cancer while the leaves are used to treat dysentery, allergy, tumour and 
impotency. The stems are beneficial in the treatment of bone cancer (Tjandrawinata et 
al., 2010). A decoction of the dried fruit is taken orally to control breast cancer, cervix 
cancer, lung disease, liver, and heart diseases. Seeds are used as external medicine for 
the treatment of skin problems and mainly for cultivation as a traditional bio-pesticide 
(De Padua et al., 1999). These proven findings are advancing current scientific 
11 
 
research in developing various herbal formulations to inhibit the growth and spread of 
breast cancer (Nagaprashanthi et al., 2012).  Figure 2.2 is a summarized diagram of 























Figure 2.2: Phytochemical constituents isolated from Phaleria macrocarpa with their 
respective biological activity. 















2.2.6 Phytochemistry  
Phytochemical studies of P. macrocarpa have proven that various parts of the plant 
contain diverse chemical constituents. Mahkoside A (4,4′ dihydroxy-2-
methoxybenzophenone-6-O-β-D-glucopyranoside), magniferin (xanthonoid),  
kaempferol-3-o-β-D-glucoside, dodecanoic acid, palmitic acid, ethyl stearate, and 
sucrose were isolated from the seeds (Zhang et al., 2006). The bark is rich in saponins, 
alkaloids, polyphenolics, phenols, flavonoid and lignans meanwhile the fruit is rich in 
tannins, cariside C3, magniferin, gallic acid and phalerin (Oshimi et al., 2008). 
Phalerin, known as benzophenone glycoside (3,4,5, trihydroxy-4-methoxy-
benzophenone-3-O-β-D-glucoside) was first isolated from leaves of P. 
macrocarpa (Hartati et al., 2005). The pericarp of fruit contains kaempferol, 
myricetin, naringin and rutin. Naringin and quercitin are found in mesocarp as well as 
seeds (Hendra et al., 2011). Phorboesters, des-acetyl flavicordin-A and 29-
norcucurbitacin derivatives have been isolated from seeds (Kurnia et al., 2008). 
Structures of representative secondary metabolites isolated from P. macrocarpa are 






























Figure 2.3: Chemical structures of some known compounds found in Phaleria 
macrocarpa. 




Myricetin - C15H10O8 Gallic acid - C7H6O5 
 
Kaempferol - C15H10O6 Naringin - C27H32O14 
Quercetin - C15H10O7 Palmitic acid- C16H32O2 
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2.2.7 Pharmacological Activities  
P. macrocarpa was commonly used for the treatment of various diseases in folk 
medicine and various pharmacological activities were reported in literature including 
anticancer, antidiabetic, anti-inflammation, antibacterial, antioxidant, and antifungal 
effects (Hending and Ermin, 2009). 
  
2.2.7(a) Anticancer activity 
Every part of P. macrocarpa including leaves, bark, stem, seed and fruits are widely 
used as traditional medicine since ancient time in treating different types of cancer 
especially against breast cancer (Faried et. al., 2007; Hendra et. al., 2011). Many 
studies have been proven scientifically that gallic acid showed significant anticancer 
activity by inhibiting cell proliferation in different cancer cell lines such as human 
melanoma cell (Lo et al., 2010), human hepatocellular carcinoma cell (Sun et al., 
2016), human small lung cancer cell (Wang et al., 2016) and ovarian cancer cell (He 
et al., 2016). For example, Faried et al. (2007) have evaluated the isolated GA from P. 
macrocarpa which inhibited cancer cell proliferation and induced apoptosis in 
esophageal cancer cell (TE-2). Besides that, ethyl acetate fraction of P. macrocarpa 
(PMEAF) was reported to inhibit cell proliferation by inducing cell death in MDA-
MB-231 breast cancer cell (Tjandrawinata et al., 2010) and also has proven its 
capability as an anti-proliferative agent  and initiates apoptotic cell death in MCF-7 
cell which is an estrogen-dependent and fast-growing cell (Tjandrawinata et al., 2010). 
 
2.2.7(b) Antidiabetic activity 
P. macrocarpa, traditionally known for its anti-diabetic properties and has been found 
to decrease the post-prandial hyperglycemia in diabetic patients. The bioassay-guided 
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fractions of P. macrocarpa fruit were examined for α-glucosidase and α-amylase 
activity to discover the anti-diabetic mechanism and potential attenuation action on 
post-prandial glucose increase. The study revealed that P. macrocarpa can lower 
hyperglycaemia in both in vitro and in vivo experiments by effectively inhibiting 
carbohydrate-hydrolysing enzymes. The natural compounds from the extract have a 
therapeutic effect on type 2 diabetes mellitus (Ali et al., 2013). Moreover, few studies 
suggested that the natural compounds from P. macrocarpa fruit extract work as 
healing treatment for type 2 diabetes mellitus (Kim et al., 2010). Another study has 
reported to decrease the blood glucose due to the presence of magniferin in the most 
active n-butanol sub-fraction of methanol extract of P. macrocarpa fruit pericarp 
(Easmin et al., 2015).  
 
2.2.7(c) Anti-inflammatory activity 
Current researches are more focused on developing drugs or dietary supplements using 
secondary metabolites of P. macrocarpa such as phalerin, saponins, and alkaloids 
which indicated anti-inflammatory properties. Hendra et al. (2011) have done anti-
inflammatory in vitro assays by using P. macrocarpa methanolic fruit extract treated 
against macrophage RAW 264.7 cell lines induced by LPS/IFN-γ. The results showed 
inhibition of inducible nitric oxide synthesis in macrophage and indicating their 
notable anti-inflammatory potential. Meanwhile, in vivo anti-inflammatory studies 
were conducted on animal model; Wistar female rats to determine the effect of 
dominant compound in P. macrocarpa; hydroxyl benzophenon glucoside. The result 
showed that the inflammation in rat treated with hydroxyl benzophenon glucoside at 
22.5 mg/kg per body weight had decreased two-fold compared to normal drug 
(Mariani et al., 2010).   
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2.2.7(d) Antibacterial activity 
Empirically, microorganisms have shown resistance to synthetic antimicrobial agents 
and this resistance are the current issues in the medical field. Therefore, investigations 
of alternative medicines from natural products are required to solve those 
complications. Flavonoids are classified under phenolic groups in plants which have 
been known to possess antimicrobial activity. The antibacterial assay of P. 
macrocarpa fruit extracts was carried out by the disc diffusion method and tested 
against Gram-negative bacteria (Enterobacter aerogenes, Escherichia coli, Klebsiella 
pneumonie, Pseudomonas aeruginosa) and Gram-positive bacteria (Bacillus cereus, 
Bacillus subtilis, Micrococcus luteus, and Staphylococcus aureus) (Hendra et al., 
2011). This study elucidated that the flavonoids compounds of P. macrocarpa fruit 
may possess antimicrobial activities which can be used as an alternative antimicrobial 
agent in pharmaceutical and cosmetic products (Hendra et al., 2011). 
 
2.2.7(e) Antioxidant activity 
Various scientific reports have proven that P. macrocarpa is a rich source of a 
polyhydroxyphenolic compound known as GA which is a natural antioxidant. 
Furthermore, phenolics compounds from the extract of P. macrocarpa have also 
indicated to have biological function as an antioxidant. Lay et al. (2014) have 
examined the antioxidant activity of P. macrocarpa fruit extract and fractions by 
determining the DPPH free radical scavenging property using the UV 
spectrophotometric method. The results revealed that an ethyl acetate fraction of P. 
macrocarpa exhibited the highest free radical scavenging activity followed by the 
methanol extract, hexane fraction, chloroform fraction and water fraction. A recent 
study was undertaken by treating fructose fed male Sprague-Dawley rats with 
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methanolic extract of P. macrocarpa resulted in the prevention of fructose-induced 
oxidative stress in rats and decreased endogenous antioxidant activity (Yanti et al., 
2015). 
 
2.2.8 Toxicological Assessment  
Scientific information and evidence on toxicology study is very crucial in terms of 
safety, quality, associated toxicity and on the side effects of long term use of the 
products. A toxicity assessment provides an estimate of how much of a chemical 
substance is needed to cause harm, in addition to the types of harm it causes. The right 
dosage differentiates a poison from a remedy (Ernest, 2011). There are different 
procedures to assess carcinogenic or non-carcinogenic effects which can elucidate the 
consequence and importance of a toxicity assessment. Toxicological studies are 
conducted by exposing animal (in vivo), cells or tissues (in vitro) to chemicals. In 
addition, intake of medicinal plants without assessing its efficacy and safety can cause 
unpredicted toxic effects that may damage the organs in the human body. Liver and 
kidney are the main targets in toxicological evaluation due to the metabolic activity 
and excretion of chemical components.  
Even though P. macrocarpa has been claimed for its abundance of valuable 
medicinal properties as therapeutic agents, it may show toxicity effect at high 
concentrations. Due to the possibility of toxicity effect, supportive toxicity study on P. 
macrocarpa is needed to evaluate the efficacy and safe concentration to produce 
promising data of P. macrocarpa in curing diseases. Chong et al. (2011), reported that 
P. macrocarpa exhibited fetotoxicity effect in female mice when fed at dose of 27 
mg/kg. Besides that, the fresh fruit of P. macrocarpa is taken orally as traditional 
medicine for treatment of ulcers by the Indonesians (Easmin et al., 2015). Butanol 
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extracts of ripened fruits of P. macrocarpa is reported to cause mild necrosis of 
proximal convoluted tubules in mice kidney at a dosage higher than 85 mg/kg (Altaf 
et al., 2013). Moreover, toxicological assessment will give a very good indication and 
the confidence to move the research to clinical trials with suggested bioactive 
compound of P. macrocarpa in future.  
 
2.2.9 Precautions/Safety for Usage 
Almost all traditional medicinal plants usage is based on knowledge, skills, practices 
and beliefs of indigenous people of different culture, and is not scientifically validated 
for its safety and effectiveness. Each drug derived from plants need appropriate 
scientific knowledge and information about therapy to prescribe and administer 
accurately. Fundamentally, some important precaution should be taken to ensure the 
plant parts are not sprayed with weed killer or pesticides. Then the samples are needed 
to be washed thoroughly or soaked in water to remove unwanted pollutants before 
being further processed as dietary or supplements.   
The bioactive components extracted from natural plant or herbs with 
therapeutic activity need to be identified and the preparation should be standardized 
by quantifying chemical constituent through acceptable analytical methods. In order 
to analyse the causes of adverse effects of the drugs, it needs a specific technical 
expertise, facilities and suitable analytical laboratories to investigate the products 
concerned. For example, the WHO guidelines on safety monitoring of herbal 
medicines in pharmaceutical industries were used to analyse the herbal products 
(WHO, 2014). Certain imperative challenges regarding effective observation of 
natural or herbal derived medicine safety are critically important. Therefore, an 
adequate protection of public health can be provided by focusing on related regulatory 
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agencies involved in producing material safety data sheet (MSDS) of the herbal 
products (Ekor, 2014).  
 
2.3 Cancer  
Cancer is currently the second leading cause of death after heart diseases worldwide 
(WHO, 2014). In Malaysia, cancer is a major cause of morbidity and mortality among 
Malaysian population. According to National Cancer Registry Data, it was estimated 
that there are nearly 40,000 new cases per year and a cumulative lifetime risk of about 
1:4. In addition, reports from the National Cancer Society of Malaysia (NCSM) 
projects presented that one in every four Malaysians is likely to develop cancer by the 
age of 75 years.  
 There are plenty of known cancer types characterized by its origin such as 
breast cancer, bladder cancer, lung cancer, brain cancer, melanoma, non-Hodgkin 
lymphoma, cervical cancer, ovarian cancer, colorectal cancer, pancreatic cancer, 
oesophageal cancer, prostate cancer, skin cancer etc. Typically, cancer can be initiated 
through genetic disorders when a defective gene in a particular chromosome is passed 
to the next generation or when imperfections in DNA replication are found in inherited 
genes (Schmid, 1963; Van Loo and Voet, 2014). An increase in the ageing population, 
obesity, physical inactivity, nutrition intake and environmental risks such as the annual 
haze in Malaysia are some of the additional factors. Several cancers are associated 
with infectious virus and bacteria such as hepatitis B virus (HBV), human 
papillomavirus (HPV), human immunodeficiency virus (HIV), and Helicobacter 
pylori (bacteria).  
Cancer is the abnormal cell growth that forms tumours and these tumours can 
be divided into ‘benign’ (non-cancerous cells) and ‘malignant’ (cancerous cells) that 
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invade and destroy healthy tissue in a process called invasion. In recent years, there is 
advancement in cancer treatments where more than cures, scientists are 
enthusiastically finding possibility of early detection and prevention of cancer (Osaki 
et al., 2015). Since, cancer requires a long time to develop, therefore, there is 
opportunities to prevent cell proliferation, mutation and cancer progression at an early 
stage. The most common type of cancer treatment is surgery which implies the primary 
treatment option for most types of cancer is to remove solid tumours. In addition, 
another two common treatments are radiotherapy that uses high-energy X-rays and 
chemotherapy that uses powerful cancer-killing medications. Although modern 
treatments aim to eliminate the cancer cells but side effects still arise with the use of 
synthetic drugs in cancer treatment (Bertrand et al., 2014).  
  
2.3.1 Breast Cancer 
Breast cancer affects women worldwide and it is the leading cause of fatality in Asia 
but it occurs less frequently in men. Originally, breast cancer cells are formed in the 
tissues of the breast and divide at an abnormally faster rate to form a lump. There are 
two types of breast cancer namely ductal carcinomas beginning in the tubes (ducts) 
and lobular carcinoma in the parts of the breast (lobules). Breast cancer rates are 
increasing with age of most women above 50’s and treatments vary depending on stage 
(Stage I, II, III and IV) of cancer (Mahmood et al., 2013). The stages of breast cancer 
are crucial factors in determining prognosis before treatment starts. Staging involves 
clinical examination, mammogram, biopsy, and certain imaging investigation such as 
chest radiograph (CXR), liver ultrasound (LUS), bone scan (BS), computed 




Surgery to remove cancerous tissue is known as ‘lumpectomy’ (remove the 
cancer and leave the healthy tissue behind) and ‘mastectomy’ (removal of all the breast 
gland tissue). Subsequently, chemotherapy treatments are given through injection of 
‘chemo’ medicine such as docetaxel, paclitaxel, vinorelbine, capecitabine, liposomal 
doxorubicin, gemcitabine, and mitoxantrone to kill cancer cells. Radiation therapy, 
which involves a high-dose of radioactive substance (brachytherapy) that injected into 
blood to destroy cancerous tissue. Final follow up with hormone therapy medicine for 
breast cancer such as tamoxifen, toremifene, and fulvestrant as an oral intake for long 
period of time with a minimum 5 years (Kuźma-Richert et al., 2011). It is a preventive 
measure to prevent gene alteration in cancer cells which blocks specific hormones that 
stimulate cancer development. Hormone medicine namely Tamoxifen, is specifically 
endorsed for women of breast cancer with hormone receptor-positive (ER- positive) 
breast cancers, but there is no effective medicine for women with hormone receptor-
negative (both ER- negative). Example of ER positive breast cancer cell lines such as 
MCF-7, T-47D, BT-474, BT-483, and 600MPE while ER negative breast cancer cell 
lines are MDA-MB-231, SkBr3, Hs578T, Evsa-T, BT-549, BT-20, and AU565 
(Niemeier et al., 2010). 
Unfortunately, most of the treatments cause side effect, different treatment 
dose response and resistance after prolonged exposure to the treatments. The synthetic 
drugs applied in chemotherapy and radiation treatment not only kill the cancer cells 
but also affect the healthy cells by causing side effect such as nausea, anaemia, 
vomiting, weakening of the immune system, diarrhoea and hair loss. Studies have 
proven that cancer cells have the ability to change and develop resistance towards 
chemotherapeutic drugs due to the prolonged intake (Kaur et al., 2016). Therefore 
current studies focus more on finding novel therapeutic agents derived from natural 
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products/plants as anticancer agents which effectively treat cancer with less/no side 
effects.  
 
2.3.2 Plant as Anticancer Agents  
Since ancient time, plants possess medical history in the treatment of cancer according 
to Hartwell (1982), where it has been acknowledged that more than 3000 plant species 
were discovered as a favourable natural medicine in treatment of cancer but some of 
this plant species were used without proper references.  
Currently there are many experiments being carried out to isolate the bioactive 
components as anti-cancer agents. The potential new anticancer drugs which are 
undergoing pre-clinical trial are selected based on molecular targets and are 
comparable or even have better outcomes than synthetic drugs. There are several plant-
derived anticancer drugs that are successfully used namely; vincristine, the 
camptothecin derivatives, topotecan and irinotecan, etoposide, derived from 
epipodophyllotoxin, and paclitaxel (Sisodiya, 2013). 
 
2.3.3 Evaluation of Cytotoxicity 
Most of the active compounds, either in the form of chemicals or drugs from natural 
products have the potential to be toxic or poisonous at highest concentration and also 
depends on individual absorption capacity. Therefore, toxicity evaluation of targeted 
natural compound is an essential criterion to provide safety data which is useful in 
further studies or during development of new anticancer agent (Gurib-Fakim, 2006). 
The suggested anticancer properties of crude extract or fractioned compounds need to 
be tested for cytotoxicity. Cytotoxicity test is a biological assessment and preliminary 
screening on tissue cells by in vitro methods to observe cell death, proliferation and 
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morphological effects. There are numerous cytotoxicity assays such as MTT assay, 
MTS assay, CyQuant, XTT, Trypan Blue and etc., which will indicate the cell 
viability, inhibitory concentration (IC) or effective concentration (EC) value of drug 
concentration-treated cell lines. The United States National Cancer Institute permits 
the anticancer cut off point for IC50 value to be below than 20 μg/mL (Kuete et al., 
2016). 
 
2.4 Cell Death  
The balances between cells division and cells death are significantly important for the 
normal growth and survival of multicellular organisms. Cell death happens when the 
cells end normal cellular functions, such as respiration, metabolism, growth and 
proliferation. Cell death can be distinguished by two different mechanisms namely 
“non-programmed cell death” due to accidental injury or shock (necrosis) and 
“programmed cell death” in terms of apoptosis. 
In addition, cell deaths are differentiated based on morphological changes 
(apoptotic, necrotic and autophagic) through various microscopic techniques and 
biochemical assays. Additionally, the caspase activation, collapse of mitochondrial 
outer membrane permeabilization and exposure of phosphatidylserine to the outer 
membrane will induce apoptosis in dying cells (Kroemer et al., 2013).  
 
2.4.1 Apoptosis  
Apoptosis or programmed cell death is a normal component of the development and 
health of multicellular organisms. Homeostasis is maintained through a balance 
between cell proliferation and cell death. It is a process of controlled cellular death 
whereby the activation of specific death-signaling pathways leads to deletion of cells 
